Compare Inti Agri Resources Tbk (IIKP) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inti Agri Resources Tbk vs Organon Pharma Indonesia Tbk. — how do they compare? Inti Agri Resources Tbk trades at Rp50 (market cap 1.68T), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Inti Agri Resources Tbk is far larger — about 16.1× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| IIKP | SCPI | |
|---|---|---|
Market Cap | 1.68T | 104.4B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inti Agri Resources Tbk
Established on March 16th 1999 in Surakarta, PT. Inti Indah Karya Plasindo conduct in HD`s type Plastick Packaging Industri. On April 1 th 2005 the Company's name has been changed to PT Inti Kapuas Arowana Tbk. Responding to growing opportunities and potentials in Arowana Fish market, PT Inti Kapuas Arowana (IIKP) repositioned its business by focusing on selling and farming of Arowana Fish. Through the company’s subsidiary, PT. Istana Bahari, IIKP entered into a partnership with traditional arowana farm in Pontianak, West Kalimantan. In parallel, the company also purchased 24 hectares (62 acres) land. They are both to be developed into a modern fish farming facility.In marketing Super Red Arowana, IIKP develops a brand name “Shelook RED” to represent the high quality standard assurance that IIKP applies in the breeding, selection, and care of its Arowana Fish.
Read more on IIKP →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
